Core Viewpoint - The article emphasizes the importance of enhancing the quality of listed companies in Shanghai, focusing on cultivating high-performing, innovative, and well-governed firms that are recognized in the market [1][2]. Group 1: Shanghai State-owned Enterprises Performance - As of the end of 2024, the total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.74 billion yuan, or 28.52% from the beginning of the year [1]. - The Shanghai Municipal State-owned Assets Supervision and Administration Commission aims to complete high-quality reforms and enhance the market value performance of state-owned listed companies [2]. Group 2: Company Highlights Shanghai Port Group - In 2024, Shanghai Port Group achieved a container throughput of 51.506 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3]. - The company's net profit attributable to shareholders reached 14.95 billion yuan, a growth of 13.3% year-on-year [3]. Huayi Group - Huayi Group reported a revenue of 44.6 billion yuan in 2024, a 9.3% increase year-on-year, with a net profit of 0.91 billion yuan, up 5.8% [5]. - The company applied for 151 patents, receiving 134 authorizations, and is focusing on strategic emerging sectors [5][6]. Shanghai Pharmaceuticals - Shanghai Pharmaceuticals achieved a revenue of 275.251 billion yuan, a 5.75% increase, and a net profit of 4.553 billion yuan, up 20.82% [6][7]. - The company is optimizing its R&D system and has established a new innovation center to enhance its open innovation ecosystem [7]. Pudong Development Bank - Pudong Development Bank reported a net profit of 45.3 billion yuan in 2024, a 23.31% increase, marking the highest growth in nearly 12 years [9]. - The bank is focusing on technology finance and has developed a comprehensive cross-border financial service system [10][11]. China Pacific Insurance - China Pacific Insurance reported a revenue of 404.089 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, up 64.9% [11][12]. - The company is enhancing its green insurance offerings and has provided coverage exceeding 147 trillion yuan in green insurance [13]. Data Harbor - Data Harbor achieved a revenue of approximately 1.721 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, up 7.49% [14][15]. - The company is focusing on IDC services and has been recognized as a top service provider in the industry [14].

Group 1: Core Insights - The Shanghai Municipal State-owned Assets Supervision and Administration Commission and the Shanghai Stock Exchange held a performance briefing to enhance the quality of state-owned listed companies and strengthen investor relations [1][2] - The total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.77 billion yuan or 28.52% from the beginning of the year [1] Group 2: Company Highlights - Shanghai Port Group achieved a container throughput of 51.51 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3] - Shanghai Port Group's net profit attributable to shareholders reached 14.95 billion yuan, a 13.3% increase year-on-year [3] - Huayi Group reported a revenue of 44.6 billion yuan, a 9.3% increase, and a net profit of 910 million yuan, up 5.8% [5][6] - Shanghai Pharmaceutical achieved a revenue of 275.25 billion yuan, a 5.75% increase, and a net profit of 4.55 billion yuan, a 20.82% increase [8][9] - Pudong Development Bank's net profit reached 45.3 billion yuan, a 23.31% increase, marking the highest growth in nearly 12 years [10][11] - China Pacific Insurance Group reported a revenue of 404.09 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, a 64.9% increase [13][14] - DataPort achieved a revenue of approximately 1.72 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, a 7.49% increase [15][16] Group 3: Strategic Initiatives - Shanghai Port Group is focusing on digital, intelligent, and green transformation to enhance its core business and sustainable development capabilities [3][4] - Huayi Group is advancing major technological projects and has filed 151 patents, with 134 granted [6][7] - Shanghai Pharmaceutical is optimizing its R&D system and has established a new innovation center to accelerate the development of a collaborative ecosystem [8][9] - Pudong Development Bank is implementing a digital finance strategy and enhancing its service efficiency through various digital platforms [10][11] - China Pacific Insurance is expanding its green insurance offerings and enhancing its technology-driven services [13][14] - DataPort is deepening its IDC service capabilities and has been recognized as a top service provider in the industry [15][16]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於控股股東及其一致行動人權益變動觸及 1%刻度的 提示性公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 5 月 10 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601 ...

Core Viewpoint - The announcement details a change in equity ownership by Shanghai Pharmaceuticals Holding Co., Ltd.'s controlling shareholder, Shanghai Industrial (Group) Co., Ltd., and its concerted party, Shanghai Industrial International Investment Co., Ltd., which has resulted in an increase in their shareholding without triggering a mandatory tender offer or affecting the company's control structure [1][2][3]. Group 1: Equity Change Details - The equity change is a result of the implementation of a previously disclosed share acquisition plan by Shanghai Industrial (Group) Co., Ltd. and its concerted party, which does not trigger a mandatory tender offer [1][3]. - Prior to the equity change, Shanghai Industrial (Group) held 1,371,116,337 shares, representing 36.974% of the total share capital of 3,708,361,809 shares. After the change, their holdings increased to 1,372,116,337 shares, accounting for 37.001% of the total share capital [2][3]. - The share acquisition plan is still ongoing, and the acquiring parties will continue to increase their shareholdings in accordance with the plan during the implementation period [1][2]. Group 2: Compliance and Legal Framework - The equity change complies with relevant laws and regulations, including the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Management Measures for the Acquisition of Listed Companies [2][3]. - The company will continue to monitor the progress of the share acquisition plan and fulfill its information disclosure obligations as required by the relevant regulatory authorities [3].

证券代码：601607 证券简称：上海医药 公告编号：临 2025-053 上海医药集团股份有限公司 关于控股股东及其一致行动人权益变动触及1%刻度的提示性公告 上海实业（集团）有限公司及其一致行动人上实国际投资有限公司保证向本公 司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 名称：上实国际投资有限公司 本次权益变动系上海医药集团股份有限公司（以下简称"上海医药"或"公 司"）控股股东上海实业（集团）有限公司（以下简称"上实集团"）及其一致行 动人上实国际投资有限公司（以下简称"上实国际"）履行此前披露的增持股份计 划所致，不触及要约收购，不会导致公司股份分布不具备上市条件，亦不会导致 公司控股股东及实际控制人发生变化。 本次权益变动前，上实集团合计持有上海医药 1,371,116,337 股，占公司 总股本的 36.974%。本次权益变动后，上实集团合计持有上海医药 1,372,116,337 股，占公司总股本的 37.001%。本次增持计划尚未实施完毕，增持主体将继续按照 相关增持计划，在增持计划实施 ...

Investment Rating - The report maintains an "Outperform" rating for Shanghai Pharmaceuticals [2][16]. Core Insights - In Q1 2025, Shanghai Pharmaceuticals achieved revenue of CNY 70.76 billion, a year-on-year increase of 0.9%, while net profit attributable to shareholders was CNY 1.33 billion, down 13.6% year-on-year, primarily due to a decline in profit contributions from the Pharmaceutical Manufacturing segment and one-time losses [3][13]. - The Pharmaceutical Service segment demonstrated strong resilience, with revenue reaching CNY 64.88 billion, up 2.6% year-on-year, driven by innovative business initiatives [3][14]. - The report forecasts revenue growth of 8% for FY2025 and 7.3% for FY2026, with net profit growth expected to be 9.3% in FY2025 and 9.9% in FY2026 [11][16]. Financial Performance Summary - Revenue for FY2023 was CNY 260.3 billion, with a projected increase to CNY 275.3 billion in FY2024 and CNY 297.3 billion in FY2025, reflecting a growth rate of 12.2%, 5.7%, and 8.0% respectively [11][16]. - The gross profit margin for FY2025 is projected at 11.2%, with a slight decrease to 11.1% in FY2026 [11][16]. - The report indicates a P/E ratio of 7.4x for FY2025 and 6.7x for FY2026, suggesting the stock is undervalued compared to its earnings potential [5][16]. Segment Performance - The Pharmaceutical Service segment's revenue includes CNY 1.8 billion from Contract Sales Organization (CSO) services, up 9.9% year-on-year, and CNY 12.5 billion from innovative drug distribution, up 23.2% year-on-year [3][14]. - The Pharmaceutical Manufacturing segment reported revenue of CNY 5.89 billion, down 15.3% year-on-year, primarily due to a high base effect from the previous year [14][16]. Valuation - The target price for Shanghai Pharmaceuticals is set at HKD 13.73, based on a discounted cash flow (DCF) model with a WACC of 6.2% and a perpetual growth rate of 3% [5][16].

Investment Rating - The report maintains an "Outperform" rating for Shanghai Pharmaceuticals [2][16]. Core Insights - In Q1 2025, Shanghai Pharmaceuticals achieved revenue of CNY 70.76 billion, a year-on-year increase of 0.9%, while net profit attributable to shareholders was CNY 1.33 billion, down 13.6% year-on-year, primarily due to a decline in profit contributions from the Pharmaceutical Manufacturing segment and one-time losses [3][13]. - The Pharmaceutical Service segment showed resilience with revenue reaching CNY 64.88 billion, up 2.6% year-on-year, driven by innovative business initiatives [3][14]. - The report forecasts revenue growth of 8% for FY2025 and 7% for FY2026, with net profit expected to grow by 9.3% in FY2025 and 9.9% in FY2026 [11][16]. Summary by Sections Financial Performance - Q1 2025 revenue was CNY 70.76 billion, with a net profit of CNY 1.33 billion, reflecting a decline due to various factors including a fine and asset disposal losses [3][13]. - The Pharmaceutical Service segment's revenue was CNY 64.88 billion, with significant contributions from innovative drug distribution and medical device businesses [3][14]. Segment Analysis - Pharmaceutical Manufacturing revenue decreased by 15.3% year-on-year to CNY 5.89 billion, impacted by a high base from the previous year, but showed a quarter-on-quarter increase of 8.0% [14]. - R&D investment in Q1 2025 was CNY 610 million, with R&D expenses remaining stable year-on-year [14]. Profitability and Valuation - The report uses a discounted cash flow model to maintain a target price of HKD 13.73, corresponding to P/E ratios of 7.4x for FY2025 and 6.7x for FY2026 [5][16]. - The gross profit margin for Q1 2025 was reported at 11.2%, with expectations for continued improvement in management efficiency and cost ratios [15].

Investment Rating - The investment rating for the company is "Buy" [7][22]. Core Views - The company reported a revenue of 707.6 billion yuan in Q1 2025, reflecting a growth of 0.87%, while the net profit attributable to shareholders was 13.3 billion yuan, down by 13.6% [2][4]. - The commercial segment showed steady growth with a revenue of 649 billion yuan, up by 2.6%, and a net profit of 8.3 billion yuan, up by 0.2%. Notably, the innovative drug business achieved a revenue of 125 billion yuan, marking a significant increase of 23.2% [3][4]. - The industrial segment faced pressure with a revenue of 58.9 billion yuan, down by 15.3%, and a net profit of 5.32 billion yuan, down by 21.1%. However, multiple innovative drug research pipelines are progressing steadily [5]. - The company's gross margin was 10.25%, a decrease of 1.19 percentage points, and the net margin was 2.32%, down by 0.34 percentage points [6]. Financial Analysis - The company slightly adjusted its profit forecast for 2025-2027, estimating revenues of 2891 billion yuan, 3057 billion yuan, and 3250 billion yuan respectively, with net profits of 47.8 billion yuan, 53.7 billion yuan, and 60.8 billion yuan [7]. - The current price-to-earnings (P/E) ratios are projected to be 14, 12, and 11 for the years 2025, 2026, and 2027 respectively [7]. Summary of Financial Data - The company’s revenue for 2023 is projected at 260,295 million yuan, with a growth rate of 12%. The net profit is expected to be 3,768 million yuan, reflecting a decline of 33% [8]. - The earnings per share (EPS) for 2025 is estimated at 1.29 yuan, with a P/E ratio of 13.9 [8].

Core Insights - The strategic partnership between Ipsen and Shanghai Pharmaceuticals aims to enhance resource integration and channel coverage for the drug Daparelix in the Chinese market, benefiting patients [1][2] - Ipsen's commitment to improving drug accessibility and patient welfare is highlighted as a significant milestone in their operations in China [1] - Shanghai Pharmaceuticals emphasizes the synergy created by combining Ipsen's brand influence with its extensive distribution network and academic promotion capabilities [1][2] Company Overview - Ipsen has been operating in the Chinese market for over 30 years, focusing on introducing high-quality products [1] - Shanghai Pharmaceuticals leads in the pharmaceutical health service sector, leveraging technological innovation and digitalization for development [2] - The CSO team of Shanghai Pharmaceuticals has nearly 10 years of industry experience, establishing a nationwide service network [2] Product Focus - Daparelix is a commonly used gonadotropin-releasing hormone analog (GnRHa) applied in various medical conditions, including prostate cancer and endometriosis [1] - The collaboration aims to deepen the product's market penetration and enhance the availability of quality healthcare services [2]

Core Viewpoint - The A-share pharmaceutical and biotechnology sector demonstrated resilience in 2024 despite a complex external environment, with innovative drugs entering a phase of realization and development progress catalyzing growth, unaffected by trade wars, positioning it as a key investment theme for 2025 [1][8]. Overall Performance - A-share pharmaceutical and biotechnology companies reported stable performance, with total revenue in 2024 reaching 2.47 trillion yuan, slightly down from 2.50 trillion yuan in 2023, and a net profit attributable to shareholders of 140.26 billion yuan [2][3]. Revenue Breakdown - The overall sector had 499 companies, with a total revenue of 24,651.04 billion yuan in 2024, reflecting a year-on-year decrease of 1.50%. The first quarter of 2025 saw total revenue of 6,037.04 billion yuan, down 6.14% year-on-year [3]. - Sub-sectors such as chemical pharmaceuticals, pharmaceutical commerce, and medical devices achieved positive revenue growth in 2024, while only the medical services sector showed positive growth in Q1 2025 [4]. Individual Company Performance - Among the companies, 234 reported revenue growth in 2024, with 59 companies exceeding a 20% increase. In terms of net profit, 231 companies saw growth, with 140 exceeding 20% [5]. - Shanghai Pharmaceuticals achieved revenue of 275.25 billion yuan in 2024, up 5.75%, with a net profit of 4.55 billion yuan, a 20.82% increase. The company also reported a significant increase in R&D investment [5]. - Jiuzhoutong reported revenue of 151.81 billion yuan in 2024, a 1.11% increase, driven by stable growth in its pharmaceutical distribution business and rapid growth in emerging sectors [6]. Market Attention - The pharmaceutical and biotechnology sector has garnered significant market attention since April, with many companies receiving institutional research interest, particularly those involved in innovative drugs [7]. - Huadong Medicine's recent annual report and Q1 performance attracted considerable institutional investor interest, focusing on product development and future industry trends [7]. Investment Outlook - Analysts remain optimistic about innovative drugs, overseas expansion, and the clearing of procurement policies, suggesting that the sector is entering a growth phase with potential in insulin, orthopedics, and certain generic drug companies [8]. - The market is expected to see increased activity in mergers and acquisitions as the pharmaceutical market undergoes a phase of concentration [8].